(:TORC)

Sep 15, 2020 08:56 am ET
Adicet Announces Completion of Merger with resTORbio
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc. (previously trading...
Aug 07, 2020 10:28 pm ET
Aug 05, 2020 07:00 am ET
Adicet Bio Receives $10 Million Product Development Milestone From Regeneron
MENLO PARK, Calif., Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the terms of its strategic collaboration with Regeneron.  ADI-002 is the first of Adicet Bio's allogeneic off-the-shelf γδ T cell product candidates to specifically target solid tumors. ADI-002 is being developed and engineered by Adicet to express a GPC3-targeting chimeric antigen receptor and IL-15. 
Jul 30, 2020 07:30 am ET
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results...
Jul 28, 2020 09:31 am ET
Thinking about buying stock in Spectrum Pharmaceuticals, Sohu.com, Southwest Airlines, resTORbio, or Vaxart Inc?
NEW YORK, July 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPPI, SOHU, LUV, TORC, and VXRT.
Jul 28, 2020 08:45 am ET
resTORbio and TrialSpark collaborate to investigate RTB-101 for COVID-19 on the Project Covalence platform
NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a collaboration with resTORbio, Inc. (Nasdaq: TORC). resTORbio is a clinical-stage biotechnology company developing innovative medicines that target the biology of aging to treat aging-related diseases.
Jul 28, 2020 07:00 am ET
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-controlled pilot study of RTB101, an investigational orally-administered potent small molecule...
Jul 24, 2020 10:28 pm ET
Jul 16, 2020 11:30 pm ET
Rigrodsky & Long, P.A. Files Class Action Suit Against resTORbio, Inc.
Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of resTORbio, Inc. (“resTORbio” or the “Company”) (NASDAQ GS: TORC) common stock in...
Jul 13, 2020 03:36 pm ET
DCOM, TORC, GRUB, and NGHC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Dime Community Bancshares, Inc. (NASDAQ GS: DCOM) regarding possible breaches of fiduciary duties and other violations of law related to Dime’s agreement to be acquired by Bridge...
Jul 13, 2020 01:33 pm ET
Moore Kuehn Encourages NGHC, TERP, GARS, and TORC Investors to Contact Law Firm
NEW YORK, July 13, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:
Jul 10, 2020 09:20 pm ET
Jul 06, 2020 09:31 am ET
Thinking about buying stock in Electrameccanica Vehicles, Cinedigm Corp, resTORbio Inc, United Airlines, or General Electric?
NEW YORK, July 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOLO, CIDM, TORC, UAL, and GE.
Jun 22, 2020 01:21 pm ET
FNJN, TORC, GRUB, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Finjan Holdings, Inc. (NASDAQ GS: FNJN) regarding possible breaches of fiduciary duties and other violations of law related to Finjan’s agreement to be acquired by affiliates of Fortress...
Jun 07, 2020 08:20 am ET
Lifshitz Law Firm, P.C. Announces Investigation of resTORbio, Inc. (TORC), Taubman Centers, Inc. (TCO), Willis Towers Watson Public Limited Company (WLTW), and Wright Medical Group N.V. (NASDAQ: WMGI)
resTORbio, Inc. (TORC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of resTORbio, Inc. (TORC) to Adicet Bio, Inc. ("Adicet"). Under the terms of the agreement, resTORbio...
Jun 04, 2020 10:15 am ET
KLXE, TORC, TERP, and PTLA SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
Rigrodsky & Long, P.A. announces that it is investigating: KLX Energy Services Holdings, Inc. (NASDAQ GS: KLXE) regarding possible breaches of fiduciary duties and other violations of law related to KLX Energy’s agreement to merge with Quintana...
May 28, 2020 07:00 am ET
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
resTORbio (Nasdaq: TORC) today announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational orally-administered potent small molecule inhibitor of target of rapamycin complex 1 (TORC1), as compared...
May 19, 2020 10:19 am ET
TCO, TORC, TERP, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Taubman Centers, Inc. (NYSE: TCO) regarding possible breaches of fiduciary duties and other violations of law related to Taubman’s agreement to be acquired by Simon Property Group, Inc....
May 15, 2020 05:24 pm ET
RESTORBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of resTORbio, Inc. - TORC
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of resTORbio, Inc. (NasdaqGS: TORC) to Adicet Bio, Inc. Under the terms of the proposed transaction, resTORbio will issue a number of shares of resTORbio common stock to Adicet stockholders. Upon closing, shareholders of Adicet will own approximately 75% of the outstanding common stock of resTORbio, while resTORbio shareholders will own only approximately 25%. KSF is seeking to determine whether this consideration and the process that led to it
May 12, 2020 09:51 am ET
KLXE, PTLA, STML, and TORC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
Rigrodsky & Long, P.A. announces that it is investigating: KLX Energy Services Holdings, Inc. (NASDAQ GS: KLXE) regarding possible breaches of fiduciary duties and other violations of law related to KLX Energy’s agreement to merge with Quintana...
May 11, 2020 01:37 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Franklin Financial Network, Inc. (FSB), resTORbio, Inc. (TORC), The Meet Group, Inc. (MEET) and Willis Towers Watson Public Limited Company (WLTW)
Franklin Financial Network, Inc. (FSB) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of FSB to FB Financial Corporation. If you are a FSB investor, and would like...
May 07, 2020 07:30 am ET
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results...
May 05, 2020 02:23 pm ET
Moore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law Firm
NEW YORK, May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:
May 04, 2020 12:58 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of resTORbio, Inc. - TORC
NEW YORK, May 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating resTORbio, Inc. ("ResTORbio" or the "Company") (NasdaqGS: TORC) relating to the creation of a combined company between the Company and Adicet Bio, Inc. Under the terms of the agreement, Adicet shareholders are expected to own approximately 75% of the combined company and resTORbio shareholders are expected to own 25%..  
May 04, 2020 12:26 pm ET
TORC, ETFC, TERP, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
Rigrodsky & Long, P.A. announces that it is investigating: resTORbio, Inc. (NASDAQ GS: TORC) regarding possible breaches of fiduciary duties and other violations of law related to resTORbio’s agreement to merge with Adicet Bio, Inc. Under the...
May 01, 2020 08:00 am ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of resTORbio, Inc.
NEW YORK, May 1, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by resTORbio, Inc. (NASDAQ: TORC) and its board of directors concerning the proposed acquisition of the company by Adicet Bio, Inc. Adicet stockholders will receive newly issued shares of resTORbio common stock, leaving Adicet stockholders to own approximately 75% of the combined company. The transaction is expected to close in the second half of 2020.
Apr 30, 2020 05:18 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of CenterState Bank Corporation (CSFL), resTORbio, Inc. (TORC), Tetraphase Pharmaceuticals, Inc. (TTPH), and The Meet Group, Inc. (MEET)
CenterState Bank Corporation (CSFL) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CSFL to South State Corporation for 0.3001 South State shares per CenterState share. If...
Apr 30, 2020 04:01 pm ET
resTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020
resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of its employees, stockholders, and other meeting participants, the company has changed the...
Apr 29, 2020 05:20 pm ET
resTORbio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of resTORbio, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm
NEW YORK, April 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between resTORbio, Inc. (NASDAQ: TORC) and Adicet Bio, Inc. is fair to resTORbio shareholders. On behalf of resTORbio shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Apr 29, 2020 09:31 am ET
Thinking about buying stock in Kura Oncology, WW International, Royal Caribbean Cruises, FuelCell Energy, or resTORbio?
NEW YORK, April 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KURA, WW, RCL, FCEL, and TORC.
Apr 29, 2020 07:00 am ET
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
resTORbio, Inc. (Nasdaq: TORC) and Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the...
Apr 03, 2020 08:00 am ET
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand
resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally administered, small molecule product candidate that is a potent inhibitor of target of rapamycin...
Mar 12, 2020 07:30 am ET
resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results...
Feb 20, 2020 08:00 am ET
resTORbio to Present at the 9th Annual Leerink Partners Global Healthcare Conference
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 9th Annual...
Feb 19, 2020 08:00 am ET
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update
resTORbio (Nasdaq: TORC) today announced interim results from the ongoing Phase 1b/2a trial of RTB101, an orally-administered small molecule potent target of rapamycin complex 1 (TORC1) inhibitor product candidate, alone or in combination with...
Nov 26, 2019 08:00 am ET
resTORbio to Present at Upcoming Investor Conferences
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that management will present at two upcoming...
Nov 15, 2019 07:00 am ET
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that top line data from the PROTECTOR 1 Phase 3...
Nov 05, 2019 07:00 am ET
resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results...
Oct 08, 2019 08:00 am ET
AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG”) today announced that it has entered into a settlement agreement with Caligan Partners LP (“Caligan”). As part of this agreement, the Board of Directors has appointed Paul Fonteyne, former Chief...
Oct 02, 2019 06:00 am ET
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019
resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, will present new data today about RTB101, the company’s...
Sep 25, 2019 08:00 am ET
resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 2019 Cantor...
Sep 23, 2019 08:09 am ET
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019
resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, has been selected to present new data from its clinical...
Aug 14, 2019 07:31 am ET
resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today reported financial results for the second quarter ended...
Aug 07, 2019 09:01 am ET
resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced the company will present a corporate overview at...
Jul 23, 2019 07:01 am ET
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
resTORbio, Inc. (Nasdaq: TORC) today announced that it has completed patient enrollment of the Phase 3 PROTECTOR 1 trial, ahead of previously announced clinical timelines, with 1,024 patients randomized. PROTECTOR 1 is the first of two global Phase...
May 20, 2019 08:00 am ET
resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in
resTORbio, Inc. (Nasdaq: TORC) today announced additional data from the Phase 2b clinical trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1). RTB101 was well-tolerated and was observed...
May 15, 2019 08:00 am ET
resTORbio Reports First Quarter 2019 Financial Results and Corporate Update
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results...
May 14, 2019 08:00 am ET
resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced the appointment of Lloyd Klickstein, M.D.,...
May 13, 2019 08:00 am ET
resTORbio to Present RTB101 Phase 2b Clinical Trial Data at American Thoracic Society 2019 International Conference
resTORbio, Inc. (Nasdaq: TORC) today announced that it will present additional results from the Phase 2b trial evaluating RTB101 (dactolisib), an oral, selective, and potent inhibitor of target of rapamycin complex 1 (TORC1), in an oral...
May 09, 2019 08:00 am ET
resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness
resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1). The two PROTECTOR Phase 3 trials...
May 01, 2019 04:01 pm ET
resTORbio to Participate at Upcoming Investor Conferences in May
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that company management will participate in two...
Apr 02, 2019 08:00 am ET
resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the initiation of a Phase 1b/2a trial of RTB101,...
Mar 22, 2019 10:02 am ET
resTORbio, Inc. Announces Closing Public Offering of Common Stock
resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the closing of its...
Mar 19, 2019 07:32 pm ET
resTORbio, Inc. Announces Pricing of Public Offering of Common Stock
resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the pricing of an...
Mar 18, 2019 04:17 pm ET
resTORbio, Inc. Announces Proposed Public Offering of Common Stock
resTORbio, Inc. ("resTORbio" or the "Company") (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced that it has...
Mar 18, 2019 04:01 pm ET
resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results
resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today provided a corporate update and reported financial results...
Mar 18, 2019 07:12 am ET
resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced plans to initiate its Phase 3 program of RTB101...
Feb 21, 2019 08:00 am ET
resTORbio to Present at 8th Annual SVB Leerink Global Healthcare Conference
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced that company management will present a...
Feb 06, 2019 08:30 am ET
resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry
resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced the appointment of Erkan Baloglu, Ph.D.,...
Jan 31, 2019 04:30 pm ET
resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative Disease
resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced it will host a key opinion leader (KOL)...
Dec 19, 2018 08:00 am ET
resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences
resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Nov 13, 2018 08:00 am ET
resTORbio Reports Third Quarter 2018 Financial Results
resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Nov 08, 2018 07:12 am ET
resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Nov 07, 2018 08:00 am ET
resTORbio to Present at Upcoming Investor Conferences in November
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Nov 06, 2018 08:00 am ET
resTORbio Appoints Michael Grissinger to its Board of Directors
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Oct 16, 2018 07:12 am ET
resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs
resTORbio, Inc. (Nasdaq: TORC) today announced additional positive results from its dose-ranging Phase 2b clinical trial of RTB101, an oral, selective and potent inhibitor of target of rapamycin complex 1 (TORC1), in respiratory tract infections...
Sep 24, 2018 08:00 am ET
resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Sep 18, 2018 08:00 am ET
resTORbio Appoints Meredith Manning as Chief Commercial Officer
resTORbio, Inc. (Nasdaq:TORC), a clinical biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the...
Aug 29, 2018 08:00 am ET
resTORbio to Present at Wells Fargo 2018 Healthcare Conference
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Aug 15, 2018 08:00 am ET
resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors
resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Aug 09, 2018 08:00 am ET
resTORbio Reports Second Quarter 2018 Financial Results
resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Jul 30, 2018 07:00 am ET
resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
Jul 25, 2018 07:00 am ET
resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101
resTORbio, Inc. (Nasdaq:TORC) today announced positive topline results from its dose-ranging Phase 2b clinical trial that enrolled 652 elderly patients at increased risk of morbidity and mortality associated with respiratory tract infections...
Jul 11, 2018 02:07 pm ET
resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older
resTORbio (Nasdaq:TORC) today announced newly published data from a Phase 2a clinical trial demonstrating that target of rapamycin complex 1 (TORC1) inhibitor treatment improved immune function and decreased incidence of all infections, including...
Jun 12, 2018 08:00 am ET
resTORbio Announces Appointment of Kerry Russell, M.D., Ph.D., as Vice President of Clinical Development
resTORbio, Inc. (NASDAQ:TORC) today announced that Kerry Russell, M.D., Ph.D., has joined the company as its Vice President of Clinical Development, a newly created position as part of the company’s effort to grow through strategic hires. In the...
Jun 01, 2018 08:00 am ET
resTORbio to Present at the Jefferies 2018 Global Healthcare Conference
resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
May 22, 2018 04:30 pm ET
resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition
resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
May 10, 2018 04:01 pm ET
resTORbio Reports First Quarter 2018 Financial Results
resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
May 09, 2018 04:05 pm ET
resTORbio to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
May 09, 2018 08:30 am ET
resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly
resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today...
May 01, 2018 04:05 pm ET
resTORbio to Present at the Deutsche Bank 43rd Annual Health Care Conference
BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that...
Mar 29, 2018 04:05 pm ET
resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results
BOSTON, March 29, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today reported financial...
Mar 19, 2018 08:00 am ET
resTORbio Announces Formation of Clinical Advisory Board
Esteemed Experts Engaged as Company Advances Clinical Development Program
Feb 20, 2018 08:00 am ET
resTORbio to Present at the 2018 RBC Capital Markets Global Healthcare Conference
BOSTON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that Joan Mannick, M.D., Chief Medical Officer,...
Feb 14, 2018 10:00 am ET
Jan 30, 2018 04:01 pm ET
resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOSTON, Jan. 30, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the closing of its initial public offering...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.